Hip Fractures May Be An Early Sign of Alzheimer’s in Older People

Summary: Researchers report they have identified biomarkers of Alzheimer’s disease in spinal fluid samples of a significant number of older patients hospitalized as a result of hip fractures. The study suggests neural alterations that lead to poor balance in older people may signify an increased risk of falls that result in hip fractures, and Alzheimer’s disease. Researchers suggest the hip fracture, therefore, may serve as an early sign of Alzheimer’s in older patients.

Source: Johns Hopkins Medicine.

In a study of older people with no clinical diagnosis or signs of dementia when hospitalized to repair hip fractures, Johns Hopkins researchers say they found biomarkers of Alzheimer’s disease in most of the patients’ spinal fluid samples. The researchers say results of their study add to evidence that brain alterations that lead to poor balance in older people may underpin both increased risk of hip-fracturing falls and Alzheimer’s disease, and that hip fracture itself may therefore serve as a first sign of undiagnosed disease.

“We studied a group of patients without a clinical diagnosis of dementia, meaning that many of our study participants were active and living independently without overt signs of Alzheimer’s disease,” said Esther Oh, M.D., Ph.D., associate professor of medicine at the Johns Hopkins University School of Medicine and associate director of the Johns Hopkins Memory and Alzheimer’s Treatment Center.

Oh cautioned that her study does not suggest that every older person who has a hip fracture has Alzheimer’s, nor should everyone hospitalized for a hip fracture undergo spinal fluid tests for disease biomarkers at this time. But it does suggest that anyone facing hip repair surgery after a fall be monitored closely for signs of post-operative delirium or other mental or cognitive problems during recovery as some people may have underlying Alzheimer’s disease, which might make them more vulnerable.

Oh also noted that physicians are now diagnosing Alzheimer’s disease much earlier, and many people live for decades after diagnosis. Although there are no cures or proven treatments, early detection and health care planning may improve coping strategies and extend independent living time.

According to the National Institute on Aging, more than 5.5 million people¾most over the age of 65¾in the U.S. are estimated to have Alzheimer’s disease.

A report on the findings was published in fall 2018 in PLOS ONE.

Oh noted that several international studies have shown that up to a quarter of older adults hospitalized for hip fracture surgery are likely to die within the following year, results suggesting that a serious medical condition may have been simmering undiagnosed prior to the falls that sent them to the hospital.

Oh’s new study was in part a response to results of research published late 2018 in JAMA Surgery by Johns Hopkins researchers, which showed that 34 percent of hip fracture patients develop delirium during their hospital stay, a condition characterized by restlessness, delusions and incoherent thoughts and speech. Because patients with Alzheimer’s disease are more likely to experience these symptoms, and because of the higher than normal mortality rate associated with hip fracture compared with other surgeries, Oh and her team designed their study to directly test hip fracture patients for Alzheimer’s disease biomarkers.

For the research, the Johns Hopkins team recruited 200 hip fracture patients admitted to The Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center from November 2011 to May 2016. Participants were an average of 82 years old, ranging from 65 to 102. Most of the participants, 74 percent, were women. Some 96 percent were white. The study also only included hip fracture patients who had received spinal (local) anesthesia before surgery so that spinal fluid samples could be collected at the time of anesthetic injection.

In 168 of the patients, the spinal fluid samples were tested for elevated levels of commonly accepted biomarkers of Alzheimer’s and other neurodegenerative diseases. The biomarkers included the proteins amyloid beta 42 (Aβ42), Aβ40, tau, and tau with a phosphate chemical group attached (p-tau). The amyloid proteins and tau are found in hallmark, tangled clumps in nerve cells, and in plaques that form in the brains of people with advanced Alzheimer’s. High levels of p-tau indicate brain injury or other types of brain cell damage.

Before surgery, participants in the study also completed the Mini-Mental State Exam and the short form of the Informant Questionnaire on Cognitive Decline in the Elderly, standard tests designed to determine mental state, memory and cognition.

hip location

Oh noted that several international studies have shown that up to a quarter of older adults hospitalized for hip fracture surgery are likely to die within the following year, results suggesting that a serious medical condition may have been simmering undiagnosed prior to the falls that sent them to the hospital. NeuroscienceNews.com image is adapted from the Johns Hopkins Medicine news release.

On the basis of those test results, participants were given a Clinical Dementia Rating, with a score of 0 being completely healthy (representing 70 participants); 0.5 meaning mild cognitive symptoms (81 participants); a score of greater than 1.0 meaning early dementia (13 participants); and a score of 2.0 meaning moderate dementia (four participants). Of the people in the study, 86 percent had abnormal Aβ levels, 65 percent had abnormal tau and 35 percent had abnormal p-tau. When the researchers specifically looked at biomarker levels in the group with a Clinical Dementia Rating of 0, they found 62 out of 70 patients, or 88.6 percent, had abnormal levels of any one of the biomarkers. In the Clinical Dementia Rating group with a score of 0.5, indicating mild cognitive impairment, 98.8 percent or 80 out of 81 participants had abnormal levels in any one of the biomarkers.

The researchers ruled out older age as a possible factor skewing their results; normally 23 to 32 percent of people between 65 and 74 years old have abnormal Aβ levels. However, in the hip fracture patients, 68 percent of people in this same age range with a Clinical Dementia Rating of 0 had abnormal levels of Aβ.

Oh’s group plans to monitor study participants for a year after each surgery to document progression and clinical dementia ratings.

Testing for Alzheimer’s disease biomarkers is not covered by Medicare and isn’t routinely performed on older adults. It can be done by an amyloid PET scan or by using biomarkers from spinal fluid, such as in this study. The PET scan test costs at least $3,000. The spinal fluid analysis is still mostly used for research, although it is commercially available in some laboratories.

About this neuroscience research article

Additional authors on the study included Kaj Blennow and Henrik Zetterberg of University of Gothenburg; George Bigelow, Karin Neufeld, Paul Rosenberg, Juan Troncoso, Nae-Yuh Wang, Frederick Sieber and Constantine Lyketsos of Johns Hopkins; and Sharon Inouye and Edward Marcantonio of Harvard Medical School.

Funding: This study was supported by the Johns Hopkins Institute for Clinical and Translational Research, which is funded in part by the National Center for Advancing Translational Sciences (UL1TR0010790), the National Institute on Aging (1K23AG043504-01, R01AG033615, P50 AG005146, R24AG054259, K07AG041835), the Rosalinde and Arthur Gilbert Foundation/AFAR New Investigator Award in Alzheimer’s disease, the Roberts Gift Fund, Swedish and European Research Councils, UK Dementia Research Institute and Swedish State Support for Clinical Research.

COI: Zetterberg is a co-founder of Brain Biomarker Solutions, has served on advisory boards of Roche Diagnostics and Eli Lilly, and has received travel support from TEVA.

Source: Vanessa McMains – Johns Hopkins Medicine
Publisher: Organized by NeuroscienceNews.com.
Image Source: NeuroscienceNews.com image is adapted from the Johns Hopkins Medicine news release.
Original Research: Open access research for “Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia” by Esther S. Oh, Kaj Blennow, George E. Bigelow, Sharon K. Inouye, Edward R. Marcantonio, Karin J. Neufeld, Paul B. Rosenberg, Juan C. Troncoso, Nae-Yuh Wang, Henrik Zetterberg, Frederick E. Sieber, and Constantine G. Lyketsos in PLOS ONE. Published September 25 2018.
doi:10.1371/journal.pone.0204695

Abstract for “Effect of Depth of Sedation in Older Patients Undergoing Hip Fracture Repair on Postoperative Delirium: The STRIDE Randomized Clinical Trial” by Frederick E. Sieber, MD; Karin J. Neufeld, MD, MPH; Allan Gottschalk, MD, PhD; George E. Bigelow, PhD; Esther S. Oh, MD; Paul B. Rosenberg, MD; Simon C. Mears, MD; Kerry J. Stewart, EdD; Jean-Pierre P. Ouanes, DO; Mahmood Jaberi, MD; Erik A. Hasenboehler, MD; Tianjing Li, PhD; and Nae-Yuh Wang, PhD in JAMA Surgery. Published November 2018.
doi:10.1001/jamasurg.2018.2602

Cite This NeuroscienceNews.com Article
Johns Hopkins Medicine “Hip Fractures May Be An Early Sign of Alzheimer’s in Older People.” NeuroscienceNews. NeuroscienceNews, 26 February 2019.
<http://neurosciencenews.com/hip-fracture-alzheimers-10825/>.
Johns Hopkins Medicine (2019, February 26). Hip Fractures May Be An Early Sign of Alzheimer’s in Older People. NeuroscienceNews. Retrieved February 26, 2019 from http://neurosciencenews.com/hip-fracture-alzheimers-10825/
Johns Hopkins Medicine “Hip Fractures May Be An Early Sign of Alzheimer’s in Older People.” http://neurosciencenews.com/hip-fracture-alzheimers-10825/ (accessed February 26, 2019).

Abstract

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia

Background
There is strong association of Alzheimer’s disease (AD) pathology with gait disorder and falls in older adults without dementia. The goal of the study was to examine the prevalence and severity of AD pathology in older adults without dementia who fall and sustain hip fracture.

Methods
Cerebrospinal fluid (CSF) was obtained from 168 hip fracture patients. CSF Aβ42/40 ratio, p-tau, and t-tau measures were dichotomized into normal vs. abnormal, and categorized according to the A/T/N classification.

Results
Among the hip fracture patients, 88.6% of the cognitively normal (Clinical Dementia Rating-CDR 0; n = 70) and 98.8% with mild cognitive impairment (CDR 0.5; n = 81) fell in the abnormal biomarker categories by the A/T/N classification.

Conclusions
A large proportion of older hip fracture patients have CSF evidence of AD pathology. Preoperative determination of AD biomarkers may play a crucial role in identifying persons without dementia who have underlying AD pathology in perioperative settings.


Abstract

Effect of Depth of Sedation in Older Patients Undergoing Hip Fracture Repair on Postoperative Delirium: The STRIDE Randomized Clinical Trial

Importance
Postoperative delirium is the most common complication following major surgery in older patients. Intraoperative sedation levels are a possible modifiable risk factor for postoperative delirium.

Objective
To determine whether limiting sedation levels during spinal anesthesia reduces incident delirium overall.

Design, Setting, and Participants
This double-blind randomized clinical trial (A Strategy to Reduce the Incidence of Postoperative Delirum in Elderly Patients [STRIDE]) was conducted from November 18, 2011, to May 19, 2016, at a single academic medical center and included a consecutive sample of older patients (≥65 years) who were undergoing nonelective hip fracture repair with spinal anesthesia and propofol sedation. Patients were excluded for preoperative delirium or severe dementia. Of 538 hip fractures screened, 225 patients (41.8%) were eligible, 10 (1.9%) declined participation, 15 (2.8%) became ineligible between the time of consent and surgery, and 200 (37.2%) were randomized. The follow-up included postoperative days 1 to 5 or until hospital discharge.

Interventions
Heavier (modified observer’s assessment of sedation score of 0-2) or lighter (observer’s assessment of sedation score of 3-5) propofol sedation levels intraoperatively.

Main Outcomes and Measures
Delirium on postoperative days 1 to 5 or until hospital discharge determined via consensus panel using Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) criteria. The incidence of delirium was compared between intervention groups with and without stratification by the Charlson comorbidity index (CCI).

Results
Of 200 participants, the mean (SD) age was 82 (8) years, 146 (73%) were women, 194 (97%) were white, and the mean (SD) CCI was 1.5 (1.8). One hundred participants each were randomized to receive lighter sedation levels or heavier sedation levels. A good separation of intraoperative sedation levels was confirmed by multiple indices. The overall incident delirium risk was 36.5% (n = 73) and 39% (n = 39) vs 34% (n = 34) in heavier and lighter sedation groups, respectively (P = .46). Intention-to-treat analyses indicated no statistically significant difference between groups in the risk of incident delirium (log-rank test χ2, 0.46; P = .46). However, in a prespecified subgroup analysis, when stratified by CCI, sedation levels did effect the delirium risk (P for interaction = .04); in low comorbid states (CCI = 0), heavier vs lighter sedation levels doubled the risk of delirium (hazard ratio, 2.3; 95% CI, 1.1- 4.9). The level of sedation did not affect delirium risk with a CCI of more than 0.

Conclusions and Relevance
In the primary analysis, limiting the level of sedation provided no significant benefit in reducing incident delirium. However, in a prespecified subgroup analysis, lighter sedation levels benefitted reducing postoperative delirium for persons with a CCI of 0.

Trial Registration
clinicaltrials.gov Identifier: NCT00590707

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles